| abstract |
The present invention relates to novel β-substituted β-aminoethylphosphonate derivatives and plasma of apo (a), Lp (a), apoB, apoB binding lipoprotein (low density lipoprotein and very low density lipoprotein) It relates to reducing levels and its use for reducing plasma levels of total cholesterol. The compounds of the present invention can also be used in combination with anti-hyperlipidemic factors, anti-atherosclerotic factors, anti-diabetic factors, anti-anginal factors, anti-inflammatory or anti-hypertensive factors to prevent the above disease states and And / or may be beneficial to the treatment. |